<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><submitter>Smith AP</submitter><funding>NIAID NIH HHS</funding><pubmed_abstract>Secondary bacterial infections can exacerbate SARS-CoV-2 infection, but their prevalence and impact remain poorly understood. Here, we established that a mild to moderate SARS-CoV-2 infection increased the risk of pneumococcal coinfection in a time-dependent, but sexindependent, manner in the transgenic K18-hACE mouse model of COVID-19. Bacterial coinfection was not established at 3 d post-virus, but increased lethality was observed when the bacteria was initiated at 5 or 7 d post-virus infection (pvi). Bacterial outgrowth was accompanied by neutrophilia in the groups coinfected at 7 d pvi and reductions in B cells, T cells, IL-6, IL-15, IL-18, and LIF were present in groups coinfected at 5 d pvi. However, viral burden, lung pathology, cytokines, chemokines, and immune cell activation were largely unchanged after bacterial coinfection. Examining surviving animals more than a week after infection resolution suggested that immune cell activation remained high and was exacerbated in the lungs of coinfected animals compared with SARS-CoV-2 infection alone. These data suggest that SARS-CoV-2 increases susceptibility and pathogenicity to bacterial coinfection, and further studies are needed to understand and combat disease associated with bacterial pneumonia in COVID-19 patients.</pubmed_abstract><journal>bioRxiv : the preprint server for biology</journal><pagination>2022.02.28.482305</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8902874</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Time-Dependent Increase in Susceptibility and Severity of Secondary Bacterial Infection during SARS-CoV-2 Infection.</pubmed_title><pmcid>PMC8902874</pmcid><funding_grant_id>R01 AI139088</funding_grant_id><pubmed_authors>Smith AM</pubmed_authors><pubmed_authors>Zalduondo L</pubmed_authors><pubmed_authors>Smith AP</pubmed_authors><pubmed_authors>Williams EP</pubmed_authors><pubmed_authors>Selvaraj M</pubmed_authors><pubmed_authors>Lane LC</pubmed_authors><pubmed_authors>Jonsson CB</pubmed_authors><pubmed_authors>Plunkett TR</pubmed_authors><pubmed_authors>Vogel P</pubmed_authors><pubmed_authors>Channappanavar R</pubmed_authors><pubmed_authors>Xue Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Time-Dependent Increase in Susceptibility and Severity of Secondary Bacterial Infection during SARS-CoV-2 Infection.</name><description>Secondary bacterial infections can exacerbate SARS-CoV-2 infection, but their prevalence and impact remain poorly understood. Here, we established that a mild to moderate SARS-CoV-2 infection increased the risk of pneumococcal coinfection in a time-dependent, but sexindependent, manner in the transgenic K18-hACE mouse model of COVID-19. Bacterial coinfection was not established at 3 d post-virus, but increased lethality was observed when the bacteria was initiated at 5 or 7 d post-virus infection (pvi). Bacterial outgrowth was accompanied by neutrophilia in the groups coinfected at 7 d pvi and reductions in B cells, T cells, IL-6, IL-15, IL-18, and LIF were present in groups coinfected at 5 d pvi. However, viral burden, lung pathology, cytokines, chemokines, and immune cell activation were largely unchanged after bacterial coinfection. Examining surviving animals more than a week after infection resolution suggested that immune cell activation remained high and was exacerbated in the lungs of coinfected animals compared with SARS-CoV-2 infection alone. These data suggest that SARS-CoV-2 increases susceptibility and pathogenicity to bacterial coinfection, and further studies are needed to understand and combat disease associated with bacterial pneumonia in COVID-19 patients.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Mar</publication><modification>2025-04-19T12:51:15.643Z</modification><creation>2025-04-19T12:51:15.643Z</creation></dates><accession>S-EPMC8902874</accession><cross_references><pubmed>35262077</pubmed><doi>10.1101/2022.02.28.482305</doi></cross_references></HashMap>